**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Rahel Schwotzer, Department of Medical Oncology and Hematology, Universtity Hospital Zurich, Switzerland

**Main Body of the Abstract**
Venetoclax (Ven), an oral BCL2 inhibitor, is a promising treatment option in patients with AL amyloidosis especially in plasma cell clones with t(11;14).
We report on the 3-year follow up data of 9 patients with relapsed/ refractory AL amyloidosis with t(11:14) and BCL2 expression treated with Ven.
8/9 patients had cardiac, and 5/9 patients had renal involvement. According to the revised Mayo risk model, 4/9 patients had stage IV disease, and 4/9 patients stage III disease, 1/9 had no troponin T measurement at baseline. All patients had BCL2 expression in >50% of the plasmacells, and all patients had t(11;14) by iFISH.
Patients had a median of two prior lines of therapy (range 1-4), including high-dose melphalan and autologous stem cell transplantation (2/9), daratumumab (9/9), bortezomib (6/9), and lenalidomide (5/9). The first hematological response, and the best hematological response were observed after 26 days (range 11-125), and after 157 days (range 35-659), respectively. The hematological overall response was 100% (7/9 CR, 2/9 VGPR). After 3 years 8/9 patients are alive. Median therapy duration was 753 days, treatment is ongoing in 3/9 patients. Cardiac response is present in 5/9 patient; renal response is present in 3/9 patients, respectively.
Venetoclax is an effective treatment option for patients with relapsed/refractory AL amyloidosis with t(11;14) and BCL2 expression. Venetoclax leads to a deep hematologic response and to improvement of organ function. Overall survival at 3 years was exceptionally high at 88.9% in this intermediate- to high-risk cohort.



3 years follow-up of Venetoclax in Relapsed or Refractory AL Amyloidosis with t(11;14) and BCL2 expression PA161 (#345)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.